Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Liabilities: 2013-2025

Historic Other Non-Current Liabilities for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $17.5 million.

  • Coherus Oncology's Other Non-Current Liabilities fell 39.83% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 39.83%. This contributed to the annual value of $29.3 million for FY2024, which is 133.49% up from last year.
  • Coherus Oncology's Other Non-Current Liabilities amounted to $17.5 million in Q3 2025, which was up 4.84% from $16.7 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Other Non-Current Liabilities registered a high of $31.3 million during Q1 2025, and its lowest value of $102,000 during Q1 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $16.7 million (2025), whereas its average is $15.5 million.
  • In the last 5 years, Coherus Oncology's Other Non-Current Liabilities tumbled by 86.42% in 2022 and then surged by 27,053.92% in 2024.
  • Over the past 5 years, Coherus Oncology's Other Non-Current Liabilities (Quarterly) stood at $750,000 in 2021, then surged by 362.27% to $3.5 million in 2022, then soared by 262.30% to $12.6 million in 2023, then skyrocketed by 133.49% to $29.3 million in 2024, then plummeted by 39.83% to $17.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $17.5 million for Q3 2025, versus $16.7 million for Q2 2025 and $31.3 million for Q1 2025.